September 7, 2021

Ticagrelor improves systemic immune-inflammation index in acute coronary syndrome patients

PICO estructurado

Does ticagrelor improve inflammatory parameters (NLR, MHR, PLR, and SII) in PCI-treated ACS patients compared to clopidogrel?

P

Población

Acute coronary syndrome (ACS) patients treated with percutaneous coronary intervention (PCI)

I

Intervención

Ticagrelor

C

Comparador

Clopidogrel

O

Resultado

Inflammatory parameters including neutrophil-to-lymphocyte ratio (NLR), monocyte-to-high-density lipoprotein ratio (MHR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII)surrogate

Ticagrelor may offer additional anti-inflammatory benefits over clopidogrel in patients with acute coronary syndrome undergoing PCI.

Resumen

NLR, MHR, PLR, and SII levels were lower in ACS patients treating with ticagrelor. Ticagrelor may improve these inflammatory parameters in percutaneous coronary intervention (PCI)-treated ACS patients compared to clopidogrel.

Ticagrelor improves systemic immune-inflammation index in acute coronary syndrome patients

PICO estructurado

Resumen

Cite This Study

Also Consider

Also Consider